Celgene | Search Results | Sutro Biopharma, Inc.

New Search

If you are not happy with the results below please do another search

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

June 15, 2019

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress Interim results... read more →

Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

May 16, 2019

SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held... read more →

Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

May 15, 2019

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress, June 15, 2019 STRO-002 Phase 1 Clinical... read more →

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

April 1, 2019

STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April... read more →

Sutro Achieves $10 Million Milestone Payment from Celgene

December 19, 2018

Sutro Achieves $10 Million Milestone Payment from Celgene Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 --... read more →

Sutro Biopharma Reports Third Quarter 2018 Financial Results

November 14, 2018

-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN... read more →

Sutro Biopharma Announces $85.4 Million Series E Round

July 26, 2018

Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in... read more →

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

April 26, 2018

SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its potential first-in-class antibody drug conjugate, or ADC, product candidate,... read more →

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

April 16, 2018

- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate... read more →

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

December 12, 2017

Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American... read more →

22 Search results for: Celgene

New Search